BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Nemaura Announces Successful SugarBEAT Interim Precision Study Results

  The results indicated that over 80% of all data between the skin-patches at each time point were within 8% of each other, with an average precision of 1.07.

  December 6, 2017

   · 

  3 min read
• Deals

  Medigene Sells U.S.-Rights for Veregen and Raises Financial Guidance 2017

  MediGene today announced the sale of the US-rights for its drug Veregen to Fougera Pharma.

  December 6, 2017

   · 

  3 min read
• Business

  Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments

  Under the terms of the license agreement, Ayala will have exclusive worldwide development and commercialization rights for BMS-906024 and BMS-986115, two gamma secretase inhibitors previously developed by BMS as a Notch inhibitor for oncology indications.

  December 6, 2017

   · 

  6 min read
• Pharm Country

  Axsome Therapeutics Announces Closing of $9.5M Registered Direct Offering

  The gross proceeds of the offering were approximately $9.5 million.

  December 6, 2017

   · 

  4 min read
• Microfluidic Mixing With MXR Now Available for Products From microfluidic ChipShop

  microfluidic ChipShop GmbH today announced that its products are now available with MXR, the world’s fastest, most adaptable microfluidic mixing chip.

  December 6, 2017

   · 

  2 min read
• Drug Development

  Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial

  AB569 is the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis.

  December 6, 2017

   · 

  3 min read
• Policy

  FDA Accepts NDA for Buprenorphine Sublingual Spray From INSYS Therapeutics

  Novel formulation of partial opioid offers potential benefits compared to current alternatives.

  December 6, 2017

   · 

  3 min read
• Business

  Domainex Appoints Chris Brown as CFO

  Chris will have a pivotal role in supporting the organisation through ongoing and significant growth and investment.

  December 6, 2017

   · 

  1 min read
• Business

  Neumentum Raises $6 Million in Series A Funding to Develop Non-opioid Pain Products and Requests Type B Meeting with FDA

  Neumentum announced that it has raised $6 million in a Series A funding round through the sale of Series A Convertible Preferred Stock. Brookline Capital Markets acted as the exclusive placement agent for the financing.

  December 6, 2017

   · 

  5 min read
• Business

  Inovio Pharmaceuticals Appoints Wendy Yarno to Its Board of Directors

  Wendy Yarno has over 25 years of experience in the pharmaceutical industry highlighted by her tenure at Merck where she served as chief marketing officer.

  December 6, 2017

   · 

  4 min read